Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Cleasby

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Bioorganic & Medicinal Chemistry Letters|November 17, 2007
Biphenyl amide p38 kinase inhibitors 1: Discovery and binding modeRichard M Angell, Paul Bamborough, Anne Cleasby, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Crystal structure of human CDK4 in complex with a D-type cyclinPhilip J Day, Anne Cleasby, Ian J Tickle, et al.
Journal of Medicinal Chemistry|September 14, 2022
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent InhibitorJeffrey D St Denis, Gianni Chessari, Anne Cleasby, et al.
Chemmedchem|March 12, 2014
Crystal structure of human soluble adenylate cyclase reveals a distinct, highly flexible allosteric bicarbonate binding pocketSusanne M Saalau-Bethell, Valerio Berdini, Anne Cleasby, et al.
Plos One|June 5, 2014
Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDOAnne Cleasby, Jeff Yon, Philip J Day, et al.
Journal of Medicinal Chemistry|January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generationAdrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Bioorganic & Medicinal Chemistry|March 13, 2019
The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitorsDavid N Deaton, Young Do, Jason Holt, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Bioorganic & Medicinal Chemistry Letters|November 17, 2007
Biphenyl amide p38 kinase inhibitors 1: Discovery and binding modeRichard M Angell, Paul Bamborough, Anne Cleasby, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Crystal structure of human CDK4 in complex with a D-type cyclinPhilip J Day, Anne Cleasby, Ian J Tickle, et al.
Journal of Medicinal Chemistry|September 14, 2022
X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent InhibitorJeffrey D St Denis, Gianni Chessari, Anne Cleasby, et al.
Chemmedchem|March 12, 2014
Crystal structure of human soluble adenylate cyclase reveals a distinct, highly flexible allosteric bicarbonate binding pocketSusanne M Saalau-Bethell, Valerio Berdini, Anne Cleasby, et al.
Plos One|June 5, 2014
Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDOAnne Cleasby, Jeff Yon, Philip J Day, et al.
Journal of Medicinal Chemistry|January 22, 2005
Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generationAdrian L Gill, Martyn Frederickson, Anne Cleasby, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Molecular Cancer Therapeutics|July 19, 2011
Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer modelsMatthew Squires, George Ward, Gordan Saxty, et al.
Bioorganic & Medicinal Chemistry|March 13, 2019
The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitorsDavid N Deaton, Young Do, Jason Holt, et al.
Pageof 2